Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure.
about
Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacementSafe Oral Triiodo-L-Thyronine Therapy Protects from Post-Infarct Cardiac Dysfunction and Arrhythmias without Cardiovascular Adverse EffectsPerioperative considerations in a hypothyroid infant with hepatic haemangioma.Role of inotropic agents in the treatment of heart failure.In vivo selective expression of thyroid hormone receptor α1 in endothelial cells attenuates myocardial injury in experimental myocardial infarction in mice.Thyroid disease and the heart.Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction.Clinical review: thyroid hormone replacement in children after cardiac surgery--is it worth a try?Pharmacological support for children with myocardial dysfunction.Thyronin treatment in adult and pediatric heart surgery: clinical experience and review of the literature.Novel pharmacological treatments for heart failure.Low Triiodothyronine Syndrome and Long-Term Cardiovascular Outcome in Incident Peritoneal Dialysis Patients.The euthyroid sick syndrome: is there a physiologic rationale for thyroid hormone treatment?Case report: severe reversible cardiomyopathy associated with systemic inflammatory response syndrome in the setting of diabetic hyperosmolar hyperglycemic non-ketotic syndrome.Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction.Molecular defects in cardiac myofibrillar proteins due to thyroid hormone imbalance and diabetes.Emerging drugs for acute and chronic heart failure: current and future developments.Thyroid hormone receptor-beta is associated with coronary angiogenesis during pathological cardiac hypertrophy.Endocrinal complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease.The nonthyroidal illness syndrome in the non-critically ill patient.Nonthyroidal illness and the cardiorenal syndrome.Thyroid hormone and heart failure: from myocardial protection to systemic regulation.Restoration of thyroid hormone balance: a game changer in the treatment of heart failure?Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor α1 in cardiac repair.Thyroid Hormone and Cardioprotection.Effects of commonly used inotropes on myocardial function and oxygen consumption under constant ventricular loading conditions.Thyroid (dys)function in heart failure: is it a potential target for medical treatment?Selective thyroid hormone receptor modulators.Thyroid hormone and cardiac disease: from basic concepts to clinical application.Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury.Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase.Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment.The two-timing thyroid.Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy.Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy.Low triiodothyronine (T3) or reverse triiodothyronine (rT3) syndrome modifies gene expression in rats with congestive heart failure.Myxoedema coma in the setting of hyperglycaemic hyperosmolar state.Effects of triiodothyronine replacement therapy in patients with chronic stable heart failure and low-triiodothyronine syndrome: a randomized, double-blind, placebo-controlled study.Comparison of therapeutic triiodothyronine versus metoprolol in treatment of myocardial infarction in rats.Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy.
P2860
Q28649731-60D00FF4-F351-4B13-8186-8E0586A36C0AQ31059046-6EAABA84-1639-41D1-95F5-4238A5085196Q32156089-BFC9A8E7-B060-4EC5-AF58-5360BDEDA4F8Q33816527-A5F557AB-18C5-414F-8956-52AA15957243Q34001618-A4C13FDC-F798-4B1A-B746-C158849927D2Q34038011-B96160DA-BCE1-412F-8D1A-ABA1D010C0FEQ34509413-68F36B9B-945D-4379-8CEE-75C72816DECBQ34529617-2B8A5BCD-054F-4AEE-8F70-B471652C48A2Q34534627-158FB0A1-942E-4E43-B5F1-B3592A430A39Q34987233-A68DC245-B2EA-4B48-89B1-1E1DCB9FC2E6Q35570949-DE33E89F-7697-4E16-8E44-06BF172081E5Q35682157-B7F34A17-973E-4C63-B598-223636EEBF46Q35727741-0ED85A0F-8635-4632-BC57-941E67E43386Q35807000-5709274C-A33A-434D-AA24-0EDC28833DBFQ36060699-7F46C2F0-349C-4E48-B064-4FA4CA1C2248Q36389347-DDFACF2E-B004-47C9-9A36-9297C6842D8DQ36758585-73F45214-EDE9-4B38-A25D-3E8677571C75Q37136915-03CC84ED-148E-4C1E-89B1-90D1F01FAE1BQ37343546-66CB49FE-8F41-438D-BD62-C4A66F96E1C0Q37801961-94278044-C796-48C7-8FA8-553A79DAA683Q38133714-F4047499-745A-4253-BEF1-F8748161D04DQ38249121-9D05E959-0A4E-4059-99B0-EACDE16B53A4Q38266177-7B85731A-334E-47F0-9B8C-1A0E3FC5DE10Q38287099-BA2C6ABA-9B55-4699-B642-2CCE9BCB9CF5Q38878221-EAA7837B-C5E9-4388-B5C1-BC958C43D36BQ39790530-789B4E20-90CC-4C19-899A-E6B69C977992Q41433604-2B9B6FA4-4B06-4381-A3C9-29EBF6FAB418Q41842445-93BEB7A3-5C3F-4C34-916B-90F6A65FCC3DQ41870176-913FA9E1-A08D-4FE4-8BD2-D00BF5BFD833Q42062288-18C7CD16-46D7-4961-82E7-F02155AFDBCDQ42139398-1B2B04DD-A897-43C9-9D84-5EAF3627F498Q44185663-DA5F258D-8882-4078-8196-0EDA137B191EQ44915713-92192649-19E4-42B6-A3DE-B0AE45CB1068Q45218588-FA9506D8-8C08-432F-A81A-281DBD0677D8Q46604600-F104AC1E-40AA-4D7D-ACBD-7BFDC6C8F16FQ46908784-CD7227CC-C8E2-43C7-8BD0-8CF6233993A5Q47604634-2C603074-9616-48B2-ADC5-3EAB15B977D4Q48002452-98375C53-2933-43EB-9E5F-05A00AA84FF6Q52630393-E5010C58-1526-4F7B-A953-23C3437F1483Q52889480-729D7B50-009E-4D7F-B331-BBC9ADE63AA9
P2860
Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Safety and hemodynamic effects ...... nced congestive heart failure.
@en
Safety and hemodynamic effects ...... nced congestive heart failure.
@nl
type
label
Safety and hemodynamic effects ...... nced congestive heart failure.
@en
Safety and hemodynamic effects ...... nced congestive heart failure.
@nl
prefLabel
Safety and hemodynamic effects ...... nced congestive heart failure.
@en
Safety and hemodynamic effects ...... nced congestive heart failure.
@nl
P2093
P1476
Safety and hemodynamic effects ...... anced congestive heart failure
@en
P2093
I J Chopra
J D Moriguchi
L W Stevenson
M A Hamilton
P304
P356
10.1016/S0002-9149(97)00950-8
P407
P577
1998-02-01T00:00:00Z